Union hospital,Tongji medical college, Huazhong university of science and techonology
Welcome,         Profile    Billing    Logout  
 4 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Xiaoping
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
NCT04738630: Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Recruiting
2
110
RoW
HX008
Taizhou Hanzhong biomedical co. LTD
Bladder Cancer
12/22
12/23
NCT04492293: An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Recruiting
2
115
RoW
ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Bladder Urothelial Cancer
12/24
06/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Recruiting
1/2
123
RoW
APG-2575, Rituximab, Ibrutinib
Ascentage Pharma Group Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
12/25
NCT05843305: A Study of BPI-452080 in Subjects With Solid Tumors

Not yet recruiting
1
87
RoW
BPI-452080
Betta Pharmaceuticals Co., Ltd.
Solid Tumor, Renal Cell Carcinoma, Von Hippel-Lindau Disease
03/25
10/25
NCT05812482: Treatment of Urethral Stricture With Urethral Drug Ball

Recruiting
N/A
150
RoW
Drug balloon dilatation, Direct vision internal urethrotomy (DVIU)
Lepu Medical Technology (Beijing) Co., Ltd.
Urethral Stricture Less Than 2 cm
10/24
02/25

Download Options